A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease

Inclusion Criteria Concurrent Medication: Allowed: * Aerosolized pentamidine. * Acute and intermittent therapy with mycostatin and mycelex. * Isoniazid, if no alternative therapy is available. Allowed for up to 2 weeks: * Acyclovir for Herpes infection (withhold didanosine during therapy). * Acute therapy with fluconazole or ketoconazole. Allowed but preferably not on a continuous basis for \> 72 hours: * Acetaminophen. * Ibuprofen. * Nonsteroidal antiinflammatory agents. Patients must be: * HIV antibody positive. * Asymptomatic or have persistent generalized lymphadenopathy. * Diagnosed with one of the listed coagulopathies. * OR Sexual partner of someone with the above criteria. Allowed: * Basal cell carcinoma or in situ carcinoma of the cervix. NOTE: * As of January, 1991 full accrual of patients with prior AZT use has been reached - NOW ACCRUING ONLY THOSE WITH NO PRIOR AZT USE. Hemophilia restriction has been lifted. Prior Medication: Allowed: * Zidovudine (AZT) for a total of = or \< 13 months. NOTE: * As of January, 1991 accrual of these patients was reached, NOW ONLY PATIENTS WITH NO PRIOR AZT. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Unexplained temperature \> 38 degrees C for more than 5 consecutive days or on more than 10 days in any 30-day period in the 2 years prior to study entry. * Unexplained diarrhea defined as at least 3 liquid stools/day persisting more than 7 days within 2 years prior to study entry. * Unintentional weight loss of \> 10 pounds or \> 10 percent of usual body weight within 2 years prior to study entry. * Oral hairy leukoplakia at any time prior to study entry. * Recurrent oral candidiasis unrelated to the use of antibiotics within 2 years prior to entry or unrelated to the use of antibiotics within the past 3 months. * Herpes zoster within 2 years prior to study entry. * Seizures within the past 6 months or currently requiring anticonvulsants for control. * Current heart disease. * Current psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy. * Gout. Concurrent Medication: Excluded: * Rifampin. * Chemoprophylaxis for Pneumocystis carinii pneumonia other than aerosolized pentamidine. * Intravenous pentamidine. * Other antiretroviral agents, experimental medication, biological response modifiers, systemic corticosteroids, cimetidine, and ranitidine. * Barbiturates. * Oral acidifying agents. Patients with a history of any of the following are excluded: * AIDS-defining opportunistic infection, advanced AIDS-related complex, or malignancy. * Acute or chronic pancreatitis. * Grade 2 or higher neuropathy based on the Neuropathy Targeted Symptom Questionnaire. * Seizures. * Zidovudine therapy for = or \> 13 months. * Heart disease. * Psychological or emotional problems sufficient in the investigator's opinion to prevent adequate compliance with study therapy. * Gout. Prior Medication: Excluded within 4 weeks of study entry: * Antiretroviral agents, including ribavirin, HPA-23, rifampin, AL721. * Excluded within 3 months of study entry: * Significant course of immunomodulating agents, such as steroids (\> 1 week), isoprinosine, thymic factors, or any other experimental drugs. * Excluded within 30 days prior to study entry: * Neurotoxic drugs. Excluded: * Didanosine (ddI). * Dideoxycytidine (ddC). * Zidovudine (AZT) if received for \> 13 months. Prior Treatment: Excluded within 3 months of entry: * Other experimental therapy. History of recent alcohol abuse.